European Journal of Cancer
Volume 38, Issue 10 , Pages 1298-1312 , July 2002

Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma

  • U Basso
    • ,
  • A.A Brandes

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +39-049-821-5931; fax: +39-049-821-5932

Received 30 May 2001 ,Revised 12 October 2001 ,Accepted 18 January 2002.

References 

  1. Henry JM, Heffner RRJ, Drillard SH, Earle KM, Davis RL. Primary malignant lymphomas of the central nervous system. Cancer. 1974;94:1293–1302
  2. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann. Intern. Med. 1993;119:1093–1104
  3. Reni M, Ferreri AJ, Garancini MP, Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients (results of a critical review of the literature). Ann. Oncol. 1997;8:227–234
  4. Blay JY, Ongolo-Zogo C, Sebban C, Carrie C, Thiesse P, Biron P. Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. Ann. Oncol. 2000;11:39–44
  5. Abrey L, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J. Clin. Oncol. 1998;16:859–863
  6. McAllister LD, Doolittle ND, Guastadisegni PE, et al.  Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery. 2000;46:51–60
  7. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachussetts General Hospital experience 1958–1989. Cancer. 1994;74:1383–1397
  8. Lutz JM, Coleman MP. Trends in primary cerebral lymhoma. Br. J. Cancer. 1994;70:716–718
  9. Werner MH, Phuphanich S, Lyman GH. The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. Cancer. 1995;76:1634–1642
  10. Eby NL, Grufferman S, Flannelly CM, Schold SC, Vogel FS, Burger PC. Increasing incidence of primary brain lymphoma in the US. Cancer. 1988;62:2461–2465
  11. Corn BW, Marcus SM, Tophan A, Hauck W, Curran WJ. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?. Cancer. 1997;79:2049–2413
  12. Ahsan H, Neugut AL, Bruce JN. Trends in incidence of primary malignant brain tumors in USA, 1981–1990. Int. J. Epidemiol. 1995;24:1078–1085
  13. Krogh-Jensen M, Amore FD, Jensen MK, et al.  Clinico-pathological features, survival and prognostic factors of primary central nervous system lymphomas (trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well defined geographical area). Leuk. Lymphoma. 1995;19:223–233
  14. Yau YH, O'Sullivan MG, Signorini D, Ironside JW, Whittle IR. Primary lymphoma of the central nervous system in immunocompetent patients in South-East Scotland. Lancet. 1996;348:890
  15. Hao D, Di Francesco LM, Brasher PM, et al.  Is primary CNS lymphoma really becoming more common? A population-based study of incidence, clinicopathological features and outcomes in Alberta from 1975 to 1996. Ann. Oncol. 1999;10:65–70
  16. Postler E, Bornemann A, Skalej M, et al.  Intracranial inflammatory tumors (a survey of their various etiologies by presentation of 5 cases). J. Neurooncol. 1999;43:209–217
  17. Paulus W, Jellinger K. Comparison of integrin adhesion molecules expressed by primary brain lymphomas and nodal lymphomas. Acta Neuropathol. (Berl.). 1993;86:360–364
  18. Jellinger KA, Paulus W. Primary central nervous system lymphomas (new pathological developments). J. Neurooncol. 1995;24:33–36
  19. Geddes JF, Bhattacharjee MB, Savage K, Scaravalli F, McLaughlin JE. Primary cerebral lymphoma (a study of 47 cases probed for Epstein-Barr virus genome). J. Clin. Pathol. 1992;45:587–590
  20. Antinori A, Larocca LM, Fassone ?, et al.  HHV-8/KSHV is not associated with AIDS-related primary central nervous system lymphoma. Brain Pathol. 1999;9:199–208
  21. Larocca LM, Capello D, Rinelli A, et al.  The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood. 1998;92:1011–1019
  22. Thompsett AR, Ellison DW, Stevenson FK, Zhu D. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood. 1999;94:1738–1746
  23. Harada K, Kurisu K, Arita K, et al.  Telomerase activity in central nervous system malignant lymphoma. Cancer. 1999;86:1050–1055
  24. Reni M, Ferreri AJM, Zoldan MC, Villa E. Primary brain lymphomas in patients with a prior or concomitant malignancy. J. Neurooncol. 1997;32:135–142
  25. Herrlinger U. Primary central nervous system lymphoma (from clinical presentation to diagnosis). J. Neurooncol. 1999;43:219–226
  26. Whitcup SM, de Smet MD, Rubin BJ, et al.  Intraocular lymphoma clinical and histopathological diagnosis. Ophthalmology. 1993;100:1399–1406
  27. Lachance DH, O'Neill BP, MacDonald DR, et al.  Primary leptomeningeal lymphoma (report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature). Neurology. 1991;41:95–100
  28. McDonald AC, Nicoll JA, Rampling R. Intramedullary non-Hodgkin's lymphoma of the spinal cord (a case report and literature review). J. Neurooncol. 1995;23:257–263
  29. Blay JY, Conroy T, Chevreau C, et al.  High dose methotrexate for the treatment of primary central nervous system lymphomas (analysis of survival and late neurological toxicity in a retrospective series). J. Clin. Oncol. 1998;16:864–871
  30. Harris NL, Jaffe ES, Stein H, et al.  A revised European-American classification of lymphoid neoplasms (a proposal from the International Lymphoma Study Group). Blood. 1994;84:1361–1392
  31. Bataille B, Delwail V, Menet E, et al.  Primary intracerebral malignant lymphoma (report of 248 cases). J. Neurosurg. 2000;92:261–266
  32. Villegas E, Villa S, Lopez-Guillermo A, Petit J, Ribalta T, Graus F. Primary central nervous system lymphoma of T-cell origin (description of two cases and review of the literature). J. Neurooncol. 1997;34:157–161
  33. Klein R, Mullges W, Bendszsus M, Woydt M, Kreipe H, Roggendorf W. Primary intracerebral Hodgkin's disease (report of a case with Epstein-Barr virus association and review of the literature). Am. J. Surg. Pathol. 1999;23:477–481
  34. Lachance DH, Brizel DM, Gockerman JP, et al.  Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma (short duration response and multifocal intracerebral recurrence preceding radiotherapy). Neurology. 1994;44:1721–1727
  35. Schwaighofer BW, Hesselink JR, Press GA, Wolf RL, Healy ME, Berthoty DP. Primary intracranial CNS lymphoma (MR manifestation). Am. J. Neuroradiol. 1989;10:725–729
  36. DeAngelis LM. Cerebral lymphoma presenting as a non enhancing lesion on computed tomographic/magnetic resonance scan. Ann. Neurol. 1993;33:308–311
  37. Lorberboym M, Wallach F, Estok L, et al.  Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. Nucl. Med. 1998;39:1366–1369
  38. Roland J, Pickut BA, Abib A, Vandevivere J, de Deyn PP. Primary cerebral lymphoma visualised by means of In-111-pentetreotide scintigraphy. Acta Neurol. Belg. 1998;98:356–359
  39. Roelcke U, Leenders KL. Positron emission tomography in patients with primary CNS lymphomas. J. Neurooncol. 1999;43:231–236
  40. Talbot JN, Haioun C, Rain JD, et al.  [18F]-FDG positron imaging in clinical management of lymphoma patients. Crit. Rev. Oncol. Hematol. 2001;38:193–221
  41. Doyle WK, Budinger TF, Valk PE. Differentiation of cerebral radiation necrosis from tumor recurrence by (18F)FDG and 82Rb positron emission tomography. J. Comput. Assist. Tomogr. 1987;11:563–570
  42. Herrlinger U. Primary central nervous system lymphoma (findings outside the brain). J. Neurooncol. 1999;43:227–230
  43. Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer. 1989;83:939–947
  44. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. 1992;10:635–643
  45. Corn BW, Dolinskas C, Scott C, et al.  Strong correlation between imaging response and survival among patients with primary central nervous system lymphoma (a secondary analysis of RTOG studies 83-15 and 88-06). Int. J. Radiat. Oncol. Biol. Phys. 2000;47:299–303
  46. Pirotte B, Levevier M, Golmann S, Brucher JM, Brotchi J, Hildebrand J. Glucocorticoid-induced long term remission in primary cerebral lymphoma (case report and review of the literataure). J. Neurooncol. 1997;32:63–69
  47. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J. Neurooncol. 1999;43:237–239
  48. O'Neill BP, Habermann TM, Witzig TE, Rodriguez M. Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone. Med. Oncol. 1999;16:211–215
  49. Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system. J. Neurosurg. 1986;65:600–607
  50. Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNLS). J. Neurooncol. 1999;43:241–247
  51. Nelson DF, Martz KL, Bonner H, et al.  Non-Hodgkin's lymphoma of the brain (can high-dose, large volume radiation therapy improves survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG) RTOG 83-15). Int. J. Radiat. Oncol. Biol. Phys. 1992;23:9–17
  52. Brandes AA, Rigon A, Monfardini S. Radiotherapy of the brain in elderly patients—contra. Eur. J. Cancer. 2000;36:447–451
  53. Nasir S, DeAngelis LM. Update on the management of primary CNS lymphoma. Oncology (Huntingt.). 2000;14:228–234
  54. Chamberlain MC, Levin VA. Primary central nervous system lymphoma (a role for adjuvant chemotherapy). J. Neurooncol. 1992;14:271–275
  55. Shibamoto Y, Sasai K, Oya N, Hiraoka M. Systemic chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma (a phase II study). J. Neurooncol. 1999;42:161–167
  56. DeAngelis LM. Primary CNS lymphoma (treatment with combined chemotherapy and radiotherapy). J. Neurooncol. 1999;43:249–257
  57. Ott RJ, Brada M, Flower MA, Babich JW, Cherry SR, Deehan BJ. Measurement of blood brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary central nervous system lymphoma. Eur. J. Cancer. 1991;27:1356–1361
  58. Balis FM, Poplack DG. Central nervous system pharmacology of antileukemic drugs. Am. J. Pediatr. Hematol. Oncol. 1989;11:74–86
  59. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy (brain tissue profiles after ventriculocisternal perfusion). J. Pharmacol. Exp. Ther. 1975;195:73–83
  60. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy for primary central nervous system lymphoma (long term outcome). J. Neurosurg. 1994;81:188–195
  61. Hiraga S, Arita N, Ohnishi T, et al.  Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J. Neurosurg. 1999;91:221–230
  62. Shapiro WR, Young F, Mehta BM. Methotrexate (distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections). N. Engl. J. Med. 1975;293:161–166
  63. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma (the next step). J. Clin. Oncol. 2000;18:3144–3150
  64. Herrlinger U, Schabet M, Brugger W, et al.  Primary central nervous system lymphoma 1991–1997. Cancer. 2001;91:130–135
  65. Schlegel U, Pels H, Oehring R, Blumcke I. Neurologic sequelae of treatment of primary CNS lymphoma. J. Neurooncol. 1999;43:277–286
  66. O'Brien P, Roos D, Pratt G, et al.  Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J. Clin. Oncol. 2000;18:519–526
  67. Rubinstein LJ, Herman MM, Long TF, Wilbur JR. Disseminated necrotizing leukoencephalopathy (a complication of treated central nervous system leukemia and lymphoma). Cancer. 1975;35:291–305
  68. O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-Hodgkin's lymphoma (survival advantages with combined initial therapy?). Int. J. Radiat. Oncol. Biol. Phys. 1995;33:663–673
  69. Mead GM, Bleehen NM, Gregor A, et al.  A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma (cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy). Cancer. 2000;89:1359–1370
  70. Schultz C, Scott C, Sherman W, et al.  Preirradiation chemotherapy with with cyclophosphamide, doxorubicin, vincristine and dexamethasone for primary CNS lymphoma (initial report of Radiation Therapy Oncology Group (RTOG) protocol 88–06). J. Clin. Oncol. 1996;14:556–564
  71. Glass J, Shustik C, Hochberg FH, Cher L, Gruber ML. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine and dexamethasone (MCHOD). J. Neurooncol. 1996;30:257–265
  72. Bessell EM, Graus F, Punt JA, et al.  Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J. Clin. Oncol. 1996;14:945–954
  73. Dent S, Eapen L, Girard A, Hugenholtz H, DeSilva V, Stewart DJ. ProMACE/MOPP and intrathecal chemotherapy for CNS lymphomas. J. Neurooncol. 1996;28:25–30
  74. Brada M, Hjiyiannakis D, Hines F, Traish D, Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int. J. Radiat. Oncol. Biol. Phys. 1998;40:1157–1162
  75. Slevin ML, Piall EM, Aherne GH, Harvey VJ, Johnston A, Lister TA. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J. Clin. Oncol. 1983;1:546–551
  76. Freilich R, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology. 1996;46:435–439
  77. Sandor V, Stark-Vancs V, Pearson D, et al.  Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J. Clin. Oncol. 1998;16:3000–3006
  78. Neuwelt EA, Goldman DL, Dahlborg SA, et al.  Primary CNS lymphoma treated with osmotic blood-brain barrier disruption (prolonged survival and preservation of cognitive function). J. Clin. Oncol. 1991;9:1580–1590
  79. Cheng AL, Yeh KH, Uen WC, Hung RL, Liu MY, Wang CH. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma (a pilot study of the BOMES protocol). Cancer. 1998;82:1946–1951
  80. Korfel A, Thiel E. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy. Leuk. Lymphoma. 1998;30:609–618
  81. Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy (preliminary results). Neurology. 1996;46:1757–1759
  82. Guha-Thakurta N, Damek D, Pollack C, et al.  Intravenous methotrexate as initial treatment for primary central nervous system lymphoma (response to therapy and quality of life of patients). J. Neurooncol. 1999;43:259
  83. Siobhan N, Rosenthal A, Ahley D, Cher L. High dose methotrexate for primary CNS lymphoma in the elderly. Neuro-Oncology. 2000;2:40–44
  84. Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Clin. Pharmacol. Ther. 2000;67:631–641
  85. Reni M, Ferreri AJ, Villa E. Second-line treatment for primary central nervous system lymphoma. Br. J. Cancer. 1999;79:530–534
  86. Herrlinger U, Brugger W, Bamberg M, Kuker W, Dichgans J, Weller M. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology. 2000;54:1707–1708
  87. Reni M, Ferreri AJ, Landoni C, Villa E. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J. Natl. Cancer Inst. 2000;92:575–576
  88. Ciordia R, Hochberg F, Batchelor T, et al.  Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma. Proc. Am. Soc. Clin. Oncol. 2000;19:165a
  89. Raizer JJ, Lisa DM, Zelenetz AD, et al.  Activity of Rituximab in primary central nervous system lymphoma—PCNSL. Proc. Am. Soc. Clin. Oncol. 2000;19:166a
  90. Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Delangre T, Tilly H. Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant. 1996;18:1021–1023
  91. Soussain C, Suzan F, Hoang-Xuan K, et al.  Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J. Clin. Oncol. 2001;19:742–749
  92. Marks R, Warnke P, Guttenberg R, et al.  Primary CNS lymphoma (PCNSL) (high dose chemotherapy with autologous PBSCT and hyperfractionated radiotherapy within first-line treatment). Ann. Oncol. 1999;10:15
  93. Ferreri AJM, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma; lessons from prospective trials. Ann. Oncol. 2000;11:927–937

PII: S0959-8049(02)00031-X

European Journal of Cancer
Volume 38, Issue 10 , Pages 1298-1312 , July 2002

Article Tools